Optimal Cerebral Perfusion Pressure Guided Therapy: Assessment of Target Effectiveness - II
Key facts
- Who runs it
- Maastricht University Medical Center
- Where
- Netherlands4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 62 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 15 May 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Optimal cerebral perfusion pressure
- Record updated
- 28 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult (>18 years old)
- Severe TBI requiring ICP-directed therapy for at least 24 hrs on the assessment of the recruiting intensive care team and/or attending neurosurgeon
- Start randomization within 24 hrs after ICU admission
Who cannot take part
- Failure to get final written informed consent
- Known pregnancy
- Moribund at presentation (e.g. bilaterally absent pupillary responses)
- Patients with a primary decompressive craniectomy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
After severe traumatic brain injury, adequate blood flow to the brain is essential for recovery. This depends on arterial blood pressure, yet intensive care units apply fixed targets to all patients - treating every brain and patient the same. This study aims to change that. With new technology, 'optimal' blood pressure can be determined for each individual brain and treatment can be tailored accordingly. This personalized approach to neurocritical care has never been tested in a randomized controlled study before. If effective in showing reduced brain damage biomarkers, it will fundamentally transform brain injury treatment and dramatically improve recovery outcomes for patients worldwide.
The 2 groups in the trial
- CPPopt treatmentTreatment being tested
The CPPopt treatment group will receive management according to the Brain Trauma Foundation (BTF) guidelines, except for the targeted cerebral perfusion pressure. Here, the calculated "optimal cerebral perfusion pressure (CPPopt)" will be targeted, with updated CPPopt targets every 4 hours. CPPopt treatment will be performed for a maximum of 5 days. If a patient still requires ICP treatment after 5 days, the standard, guideline-based treatment will be followed. CPPopt treatment can be shorter than 5 days, if ICP measurement is no longer required, if a patients wakes up, or if a patient dies.
Treatment: Optimal cerebral perfusion pressure
- Control groupNo study treatment, for comparison
The intervention group will receive standard brain trauma management according to the Brain Trauma Foundation (BTF) guidelines, including the standard cerebral perfusion pressure target of 60-70 mmHg.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- CPPopt Guided Therapy: Assessment of Target Effectiveness - II
- Record updated
- 28 September 2026